home / stock / clcs / clcs short
Short Information | Cell Source Inc (OTCMKTS:CLCS)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 96,801 |
Total Actual Volume | 309,634 |
Short Trends | |
---|---|
Cover Days | 10 |
Short Days | 3 |
No Change Days | 7 |
Averages | |
---|---|
Average Short Volume | 4,840 |
Average Short Percentage | 29.64% |
Is there a CLCS Short Squeeze or Breakout about to happen?
See the CLCS Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
08-02-2024 | $0.36 | $0.39 | $0.39 | $0.36 | 1,180 | 500 | 42.37% |
08-01-2024 | $0.39 | $0.35 | $0.39 | $0.25 | 15,600 | 9,150 | 58.65% |
07-31-2024 | $0.35 | $0.4 | $0.41 | $0.33 | 19,615 | 7,895 | 40.25% |
07-30-2024 | $0.55 | $0.35 | $0.55 | $0.25 | 18,687 | 100 | 0.54% |
04-16-2024 | $0.35 | $0.398 | $0.398 | $0.35 | 2,100 | 100 | 4.76% |
04-15-2024 | $0.4 | $0.3975 | $0.4 | $0.29 | 12,650 | 4,600 | 36.36% |
04-08-2024 | $0.25 | $0.5 | $0.51 | $0.25 | 8,020 | 100 | 1.25% |
04-01-2024 | $0.6 | $0.39 | $0.6 | $0.39 | 14,500 | 200 | 1.38% |
03-27-2024 | $0.59 | $0.58 | $0.62 | $0.311 | 3,513 | 641 | 18.25% |
03-25-2024 | $0.59 | $0.59 | $0.59 | $0.59 | 10,000 | 490 | 4.9% |
03-22-2024 | $0.59 | $0.59 | $0.59 | $0.59 | 1,055 | 950 | 90.05% |
03-21-2024 | $0.49 | $0.59 | $0.59 | $0.49 | 12,164 | 2,700 | 22.2% |
03-19-2024 | $0.43 | $0.4275 | $0.43 | $0.33 | 21,325 | 10,650 | 49.94% |
03-18-2024 | $0.43 | $0.3075 | $0.43 | $0.3075 | 40,162 | 17,425 | 43.39% |
03-15-2024 | $0.25 | $0.43 | $0.43 | $0.25 | 563 | 300 | 53.29% |
03-07-2024 | $0.35 | $0.4 | $0.4 | $0.35 | 5,400 | 400 | 7.41% |
03-01-2024 | $0.35 | $0.4 | $0.4 | $0.35 | 3,500 | 1,000 | 28.57% |
02-26-2024 | $0.35 | $0.39 | $0.4 | $0.35 | 32,300 | 15,300 | 47.37% |
02-22-2024 | $0.46 | $0.4575 | $0.46 | $0.29 | 61,200 | 23,300 | 38.07% |
02-21-2024 | $0.34 | $0.4 | $0.4 | $0.34 | 26,100 | 1,000 | 3.83% |
News, Short Squeeze, Breakout and More Instantly...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Darlene Soave Joins Cell Source's Board of Directors PR Newswire NEW YORK , April 1, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ( " Cell Source" or "the Company"), is the world leader in Veto Cell based innovative immunotherapy and today announced tha...
USPTO Issues New Patents for Cell Source's Veto Cell Technology Patents Validate Veto Cells as a Critical Enabler for Cell Therapies Such as CAR-T, TCR, and NK as well as a Powerful, Stand-alone Immunotherapy in the Treatment of Cancer, Viral and Bacterial Infections PR News...